The priming of human mesenchymal stem cells with IFN-γ modulated their immunosuppressive capacity and resulted in clinical improvement and prolonged survival in a murine model of graft vs. host disease [44]. The gene discussed is IFNG; the disease is glycogen storage disease VI.